Navigation Links
Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector

IRVINE, Calif., Feb. 11, 2013 /PRNewswire/ -- Based on its recent analysis of the companion diagnostics market, Frost & Sullivan recognizes ResearchDx with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. In an industry where the trend in the contract services sector is moving toward greater specialization and focusing on a few key capabilities, ResearchDx's mission to be a sole provider and affordable option for contract diagnostic development is both unique and entrepreneurial.

"ResearchDx originated the concept of a contract diagnostic organization for biopharmaceutical companies and diagnostic companies, which is analogous to the services a contract research organization would provide for drug clinical trials," observed Frost & Sullivan Senior Industry Analyst Winny Tan . "The company can provide contract R&D across the entire development and commercialization process for companion diagnostics for pharmaceutical companies, in vitro diagnostic (IVD) companies and clinical laboratories, strongly positioning it at a critical time in the market for impressive and sustainable growth over the long term."

ResearchDx provides services including assay development, validation, and optimization for a clinical setting; study management and regulatory submissions; validation of laboratory-developed tests; test deployment in its Clinical Laboratory Improvement Act (CLIA) and College of American Pathologists (CAP) accredited laboratory; and in vitro diagnostic (IVD) kit manufacturing in its good manufacturing practice (GMP) facility.

ResearchDx's strategy has proved to be a winning one; the early stage company has achieved 150 percent annual revenue growth consistently for the past three years. As the first fully integrated contract diagnostic organization, the company is an extremely valuable partner for accelerating the regulatory approval and commercialization of diagnostic products.

"ResearchDx leads in delivering customer value, because customers receive the best solution that is matched to their specific needs," explained Tan. "Further, the company leverages more than 20 years of clinical diagnostic laboratory industry experience to offer expert advice. Unlike many of its competitors that offer diagnostic development limited to their proprietary platforms, ResearchDx's solutions are driven by the customer's diagnostic needs, rather than any one diagnostic platform."

For its extraordinary performance in the contract diagnostics organization sector, Frost & Sullivan recognizes ResearchDx as the 2012 North American Entrepreneurial Company of the Year Award recipient.

Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneurial spirit by devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in business processes, leadership in customer value as well as market penetration. In short, the award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ResearchDx

ResearchDx is The Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx offers the services and solutions to meet complex diagnostics development needs.   ResearchDx's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting.  Additional information is available at  

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation


Mireya Espinoza    
P: 210. 247.3870    
F: 210.348.1003    

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gains from a Growing Patient Pool for Cardiac Rhythm Management Devices Offset by Lower Product Pricing, Observes Frost & Sullivan
2. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
3. Best Practices Involving Product Innovation and Creation of Value Vital for Customer Retention, Finds Frost & Sullivan
4. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
5. Medical Devices 2013: A Frost & Sullivan Executive MindXchange- Sustaining the Vitality of the Industry and Your Company
6. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
7. Americas Interest in Obesity Surgery Soars Following its Success in Europe and ROW, Finds Frost & Sullivan
8. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
9. Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan
10. Frost & Sullivan: Appropriate Channel Partners Vital in the Highly Fragmented Medical Devices Distribution Market in VITSK
11. Frost & Sullivan: TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... CAMBRIDGE, Mass. , Oct. 8, 2015 /PRNewswire/ ... has awarded approximately $40 million to the Broad ... whole genome sequencing of 20,000 individuals, as well ... sequencing and metabolite profiling. Trans-Omics for ... an initial step toward a larger initiative, which ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
Breaking Medicine Technology:
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David ... be using the Roche LightCycler ® 480 System, a ... gene expression and genetic variation, in advanced cancer research. ... 480 System to support several key areas of research it ...
... 2011 /PRNewswire/ -- Royal Philips Electronics ... States availability of the Ingenia MRI system, the ... Previously available in Europe, Canada and Japan, the ... Food and Drug Administration. Driven by Philips commitment ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint Cup ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for the ... and all of the stars of the NASCAR Sprint Cup Series. As part ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled Bold ... Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement was ... a celebratory gala on October 1st. , Many of the features of the ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... now offering a special promotion on Invisalign, the orthodontic system that uses clear, ... The aligners are almost invisible against the teeth, which allow patients to complete ...
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
Breaking Medicine News(10 mins):
... , New Report Highlights Best and Worst State ... Va., Sept. 10 A new report by The Vision Council, ... for children entering school are inconsistent, impeding children,s ability to succeed ... visual processing of information, undetected vision problems can severely impact a ...
... largest network of Hispanic health advocates joins President Obama,s efforts to improve ... , WASHINGTON, Sept. 9 "There was a clear ... reform. We need to work together to get the job done and ... our history, it is essential that we do this to support America,s ...
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings ... the launch of its initial public offering of 33,333,333 shares ... is expected to be between $11.00 and $13.00 ... of common shares by Select, and Goldman, Sachs & Co., ...
... 9 As the nation awaits President Obama,s address on ... Philanthropic Collaborative (TPC) sent today a letter to the President ... foundations in the field of health. , , ... the social and economic effectiveness of health-related philanthropic activities. ...
Cached Medicine News:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: